Necker–Enfants Malades Hospital

CareDx Advances Global Transplant Patient Care at ESOT Congress 2023

Retrieved on: 
Thursday, September 14, 2023
Biotechnology, Surgery, Hospitals, Health, Clinical Trials, Abstract, DNA, Paris Institute for Advanced Study, Comparison, Nucleic acid thermodynamics, Transplant, Doctor of Philosophy, Necker–Enfants Malades Hospital, Organ transplantation, Teaching hospital, University Hospital of Zürich, Associate, Congress, Plasma, Lung transplantation, Nephrology, Local, MD, Patient, Risk, Medical University of Vienna, UZ Leuven, Harbin Medical University, Paris, European Society for Primary Immunodeficiencies, Caregiver, Dentistry, Medical device, Epidemiology

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
  • CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA.
  • “We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx.
  • CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023.

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

Retrieved on: 
Wednesday, July 19, 2023
IPN, Skeleton, Civil service commission, ADR, Fibrodysplasia ossificans progressiva, Ipsen, Clinical trial, Committee on Herbal Medicinal Products, Necker–Enfants Malades Hospital, Life expectancy, Committee, Research and development, Development, European Commission, FOP, Patient, MOVE, Arrest, Joint, Diagnosis, Committee for Medicinal Products for Human Use, Heterotopic ossification, Death, Disease, Caregiver, CHMP, Pharmaceutical industry, Nursing, Euronext, Research

Palovarotene is the first treatment to be submitted anywhere in the world for regulatory approval for FOP, an ultra-rare disease with approximately 900 known cases worldwide.

Key Points: 
  • Palovarotene is the first treatment to be submitted anywhere in the world for regulatory approval for FOP, an ultra-rare disease with approximately 900 known cases worldwide.
  • “We worked tirelessly to bring a greatly needed treatment option to patients living with FOP in the E.U.,” said Howard Mayer, Executive Vice President and Head of Research and Development for Ipsen.
  • We are therefore disappointed that the European Commission decided not to approve this treatment for patients with FOP in Europe.
  • This included MOVE, the first and largest Phase III clinical trial for FOP, a condition that causes abnormal bone growth.

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

Retrieved on: 
Friday, May 26, 2023
IPN, HO, ADR, Ipsen, European Medicines Agency, Committee on Herbal Medicinal Products, Necker–Enfants Malades Hospital, Palovarotene, Medicine, Inflammation, Life expectancy, Committee, Development, FOP, Patient, MOVE, Joint, Committee for Medicinal Products for Human Use, Heterotopic ossification, CHMP, Chronic pain, News, Fibrodysplasia ossificans progressiva, Safety, Disease, Pharmaceutical industry, Euronext, Research

Palovarotene is the first medicine to be submitted for regulatory approval for FOP.

Key Points: 
  • Palovarotene is the first medicine to be submitted for regulatory approval for FOP.
  • are for managing the symptoms caused by FOP, such as inflammation and chronic pain and not the underlying disease.
  • and for the clinicians managing this chronic and progressive disease,” said Dr. Genevieve Baujat, Clinical Geneticist Consultant at Necker-Enfants Malades Hospital, Paris, France.
  • “Many of my colleagues and I have been waiting for a long time for a treatment that can help us manage the devastating disease that is FOP.

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference

Retrieved on: 
Tuesday, April 25, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Experience, Immunogenetics, HLA, Nucleic acid thermodynamics, Histocompatibility, UTR, NGS, Platinum, MicroRNA, Chimera, Ambiguity, Teaching hospital, Regulation, Patient, Necker–Enfants Malades Hospital, National Institute of Allergy and Infectious Diseases, Medicine, Risk assessment, Hospital, Massive parallel sequencing, Phenotype, Conference, Caregiver, Pharmaceutical industry, Dentistry, Medical device, EU

“We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • “We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.
  • For post-transplant, CareDx offers AlloSeq HCT* chimerism testingand AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively.
  • CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.
  • CareDx will sponsor a symposium “Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes” on Thursday, April 27.

AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

Retrieved on: 
Wednesday, March 15, 2023
LIVE, MD, Necker–Enfants Malades Hospital, Euronext, MDA, CET, Doctor of Philosophy, Q&A, Science, Broadcasting

AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON THURSDAY MARCH 16, 2023, FROM 6PM TO 7PM CET

Key Points: 
  • AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON THURSDAY MARCH 16, 2023, FROM 6PM TO 7PM CET
    AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform.
  • This live webcast will provide further details on:
    The therapeutic potential of AB8939, demonstrated through a series of preclinical experiments
    The following attendees will participate to the live webcast:
    Olivier Hermine, MD, PhD, Head of the hematological department at the Necker-Enfants Malades hospital, Paris, France
    The presentation will be followed by a Q&A session with the management of AB Science.
  • Dial in numbers to listen the live webcast:
    Dial in number for the US: +1 646 722 4916
    Dial in number for France: +33 1 72 72 74 03
    Dial in number for countries outside US and France: Numbers for other countries are listed on the webcast page

Diabeloop: Launch of a Multi-Country Clinical Study in Adolescents and Young Adults With T1D

Retrieved on: 
Thursday, February 23, 2023
Diabetes, Automated insulin delivery system, Prince Sultan Advanced Technology Research Institute, Treatment, CEA-Leti: Laboratoire d'électronique des technologies de l'information, International Conference on Availability, Reliability and Security, T1D, Patient, Trial of the century, Necker–Enfants Malades Hospital, Conference, Nutrition, German Diabetes Center Mergentheim, Social environment, Glycated hemoglobin, Ageing, Pharmaceutical industry, Dietary supplement, Birth control

BERLIN, Feb. 23, 2023 (GLOBE NEWSWIRE) -- At the International Conference on Advanced Technologies & Treatments for Diabetes, Diabeloop, a leader in Automated Insulin Delivery technology, announces the launch of a clinical study in adolescents and young adults with T1D, in France, Belgium and Germany.

Key Points: 
  • BERLIN, Feb. 23, 2023 (GLOBE NEWSWIRE) -- At the International Conference on Advanced Technologies & Treatments for Diabetes, Diabeloop, a leader in Automated Insulin Delivery technology, announces the launch of a clinical study in adolescents and young adults with T1D, in France, Belgium and Germany.
  • The wearable, lightweight patch pump will optimize comfort for the 50 adolescents and young adults with T1D, aged from 12 to 18 years old, enrolled in this study.
  • Nevertheless, for many adolescents, it remains a burden to enter carb counts even during automated insulin therapy.
  • We are eager to study new approaches to reduce this burden in our clinical research center like this international collaborative study in adolescents and young adults," declares Prof. Thomas Danne.

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

Retrieved on: 
Friday, January 27, 2023
Stem Cells, Biotechnology, FDA, Professional Services, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Finance, HO, ADR, Tendon, Life expectancy, Ligament, MOVE, CHMP, Necker–Enfants Malades Hospital, Diagnosis, Development, FOP, Tissue, Safety, IPN, Patient, Committee, EMA, Committee for Medicinal Products for Human Use, European Medicines Agency, Fibrodysplasia ossificans progressiva, Death, Disease, Prevalence, Medical imaging, Pharmaceutical industry, Ipsen, Euronext

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP).

Key Points: 
  • Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP).
  • there are currently only symptomatic treatments for FOP, which do not reduce the formation of extra-skeletal bone in patients with the condition.
  • Ipsen will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing palovarotene clinical trial program.
  • We in the FOP community have been waiting a long time for innovations to treat this disabling disease.”

French Startup Sonio raises €10M through the European Innovation Council Accelerator to improve the health of women and children through AI

Retrieved on: 
Tuesday, December 20, 2022
Health Technology, Other Health, Technology, Practice Management, Professional Services, General Health, Women, Venture Capital, Children, Other Technology, Family, Biotechnology, Software, Consumer, Health, Patient, Lifecell, CE, Maternal–fetal medicine, Pregnancy, Health, Necker–Enfants Malades Hospital, Prenatal care, AI, EIC, Knowledge, Diagnosis, Brosset, Genomics, Pharmacy management system, Birth, École Polytechnique, Artificial intelligence, Software as a service, Research, Artificiality, Woman, Pharmaceutical industry, Medical imaging

Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies.

Key Points: 
  • Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies.
  • For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator.
  • A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.
  • Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.

One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

Retrieved on: 
Tuesday, September 13, 2022
Oncology, Health, Medical Devices, Stem Cells, Genetics, Other Health, Biotechnology, Therapy, Research institute, Trial of the century, Paris Descartes University, Algorithm, Institute, Transplant, Biomarker, Hospital, Coronavirus Scientific Advisory Board (Turkey), PIA, BPI, List of life sciences, Partnership, VCS, MD–PhD, Sofinnova, Patient, Program, Single-cell analysis, Cancer, Intelligence, CEO, Necker–Enfants Malades Hospital, Doctor of Philosophy, Saint Joseph Hospital, Barbados, AI, Larynx, Curie Institute (Paris), Medical device, Pharmaceutical industry, French Institute for Research in Computer Science and Automation

This new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance.

Key Points: 
  • This new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance.
  • One Biosciences will evaluate samples from patients enrolled at the Hartmann Clinic and Paris Saint-Joseph Hospital, in partnership with the Research Center of Institut Rafal (Institut Rafal Centre de Recherche).
  • One Biosciences has also benefited from BPI Frances support through non-dilutive grants (BFTE, PIA and Aide au Dveloppement DeepTech).
  • Dr. Magali Richard, co-founder of Home Biosciences and CEO of One Biosciences, said "We have assembled a unique discovery engine in a record timeframe.

Sensorion Reports 2021 First Half Results

Retrieved on: 
Monday, September 27, 2021
Medical Devices, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Necker–Enfants Malades Hospital, Clinical trial, Partnership, Natural history study, Sonova, Research, Review, Diagnosis, Hearing loss, GJB2, Solution, Institut Pasteur Korea, Particle-size distribution, Huber loss, Patient, Cisplatin, Population, Anomaly, Adult, OTOF, Deafness, CEO, Pathology, CTA, Program, Strategic planning, Pasteur Institute, NHS, CIO, Trial of the century, Science, HIV disease progression rates, Hearing, Breast implant, AAV, Cochlear Limited, Mutation, EMA, Dentistry, Pharmaceutical industry, Vaccine, Medical device

Many elements of Sensorions strategic planning came together in a successful first half of 2021.

Key Points: 
  • Many elements of Sensorions strategic planning came together in a successful first half of 2021.
  • Since not all of the patients have yet completed their 28-day end of treatment visit, Sensorion will continue the recruitment until the end of October 2021.
  • Following this initial success, Sensorion and Cochlear announced the initiation of a Phase 1 clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation on September 8, 2021.
  • The study will be sponsored by Sensorion and the proposed design is expected to be submitted to regulatory authorities during H2 2021 (see post-closing events).